Cures, tuberculosis, and deterritorialized biomedical narratives

Paul H. Mason*, Greg Fox, Jennifer Ho, Chris Degeling

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


In the essay “Cures” (Public Culture, September 2016), Bharat Venkat examines how biomedical scientists, since the time of Robert Koch (1843–1910), have contested what counts as trustworthy evidence of a cure for tuberculosis. Widespread cultural shifts accompanied these medical debates and developments. Randomized controlled trials now dominate as an evidentiary form in tuberculosis control with implications for how global health efforts roll out across diverse cultural contexts. A pharmaceutical approach drives the international export of a capsular cure to the neglect of providing sanatorium care, addressing disease transmission, and curbing drug resistance. In response to Venkat’s essay, Paul Mason and colleagues highlight how a biomedical narrative about tuberculosis became deterritorialized from high-income countries where new tuberculosis cases were decreasing, and reterritorialized in low-income countries where tuberculosis incidence was increasing. Pharmaceutical models of disease control have proven convincing and popular, but in going global they have had unintended consequences.
Original languageEnglish
Pages (from-to)269-276
Number of pages8
JournalPublic Culture
Issue number2
Publication statusPublished - 1 May 2018


  • biomedical narrative
  • deterritorialization
  • epidemiology
  • infectious disease
  • tuberculosis


Dive into the research topics of 'Cures, tuberculosis, and deterritorialized biomedical narratives'. Together they form a unique fingerprint.

Cite this